Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

In 2019, about 463 million people suffered from diabetes and over 2 million people lost their lives to its complications, including common cardiovascular complications such as heart attacks and strokes. We need to discover new ways to combat diabetes and its complications to improve the quality of life and prolong the survival of millions of patients.

High blood sugar is toxic for blood vessels and this toxic effect is believed to be responsible for the cardiovascular complications of diabetes, such as heart attacks and strokes. Insulin is a common treatment used to reduce blood sugar levels in people with diabetes – usually administered with an insulin pen or pump.

But much to scientists’ surprise, clinical trials have shown that insulin treatment doesn’t reduce the risk of heart attacks and strokes, even though it greatly reduces sugar in the bloodstream. This means that controlling blood sugar with insulin is not enough to prevent damage in the blood vessels of patients with diabetes. Why does this happen? What are we missing in this chain of events?

Read the full article on The Conversation website, written by Ioannis Akoumianakis and Charalambos Antoniades (Radcliffe Department of Medicine)

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.